Search Thermo Fisher Scientific
Element Search
Structure Search
Thermo Scientific Chemicals
Rifampin, 95%
Rifampin (rifampicin), CAS # 13292-46-1, is a synthetic rifamycin antibiotic that works by inhibiting RNA and DNA synthesis and exhibits activity against the tuberculosis microbe.
Have Questions?
Change view
Catalog number FSA455620050
Price (MYR)
1,205.00
EA
Quantity:
5 g
Price (MYR)
1,205.00
EA
Specifications
Chemical Name or MaterialRifampin
TypeRifampicin
CAS13292-46-1
Health Hazard 1Warning
Health Hazard 2GHS H Statement Harmful if swallowed. Causes skin irritation. Causes serious eye irritation. May cause respiratory irritation.
View more
This Thermo Scientific Chemicals brand product was originally part of the Acros Organics product portfolio. Some documentation and label information may refer to the legacy brand. The original Acros Organics product / item code or SKU reference has not changed as a part of the brand transition to Thermo Scientific Chemicals.
General Description
• Rifampin is a rifamycin class antibiotic synthesized to resemble the compound isolated from Amycolatopsis rifamycinica
Applications
• Rifampin can be used as a bacteriostatic that prevents RNA and DNA synthesis, particularly in mycobacteria
• It may also act as an antineoplastic, a neuroprotective, and inhibitor of angiogenesis
RUO – Research Use Only
General References:
- Tarakji, K.G.; Mittal, S.; Kennergren, C.; Corey, R.; Poole, J.E.; Schloss, E.; Gallastegui, J.; Pickett, R.A.; Evonich, R.; Philippon, F.; McComb, J.M., Roark, S.F.; Sorrentino, D.; Sholevar, D.; Cronin, E.; Berman, B., Riggio, D.; Biffi, M.; Khan, H.; Silver, M.T.; Collier, J.; Eldadah, Z.; Wright, D.J.; Lande, J.D.; Lexcen, D.R.; Cheng, A.; Wilkoff, B.L. WRAP-IT Investigators. Antibacterial Envelope to Prevent Cardiac Implantable Device Infection. N Engl J Med. 2019, 380(20), 1895-1905.
- Swindells, S.; Ramchandani, R.; Gupta, A.; Benson, C.A.; Leon-Cruz, J.; Mwelase, N.; Jean Juste, M.A.; Lama, J.R.; Valencia, J.; Omoz-Oarhe, A.; Supparatpinyo, K.; Masheto, G.; Mohapi L, da Silva Escada, R.O.; Mawlana, S.; Banda, P.; Severe, P.; Hakim, J.; Kanyama, C.; Langat, D.; Moran, L.; Andersen, J.; Fletcher, C.V.; Nuermberger, E.; Chaisson, R.E., BRIEF TB/A5279 Study Team. One Month of Rifapentine plus Isoniazid to Prevent HIV-Related Tuberculosis. N Engl J Med. 2019, 380(11), 1001-1011.